2023
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.
Morris M, Ulaner G, Halperin D, Strosberg J, Mehr S, Li D, Soares H, Anthony L, Kotiah S, Jacene H, Pavel M, Kunz P, Ferreira D, Li J, Ma K, Rearden J, Moran S, Hope T, Singh S. ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis. Journal Of Clinical Oncology 2023, 41: 4132-4132. DOI: 10.1200/jco.2023.41.16_suppl.4132.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsAdverse eventsGEP-NETsTarget dose-limiting toxicity (DLT) rateDose de-escalation studyTreatment-related serious AEsDose-limiting toxicity rateData review committeeDe-escalation studiesECOG PS 0Phase 3 doseSomatostatin analogue therapySerious adverse eventsGastroenteropancreatic neuroendocrine tumorsStandard of careSomatostatin receptor subtypesInitial safety analysisSerious AEsAnalogue therapyPS 0Dose escalationKBq/Neuroendocrine tumorsToxicity ratesDisease progression
2017
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Journal Of Clinical Oncology 2017, 35: 348-348. DOI: 10.1200/jco.2017.35.4_suppl.348.Peer-Reviewed Original ResearchGlobal health statusMidgut NETHealth statusHigh-dose octreotide LARNETTER-1 trialPhase III trialsProgression-free survivalEORTC QLQ-30Health-related qualityHormone-related symptomsMidgut neuroendocrine tumorsNeuroendocrine tumor progressionImpact of treatmentQuality of lifeOctreotide LARIII trialsQLQ-30Patients' QoLNeuroendocrine tumorsQOL analysisLu-DOTATATEDisease progressionLife findingsPatientsBaseline scores
2014
Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma
Shultz DB, Chan C, Shaffer JL, Kunz PL, Koong AC, Chang DT. Postradiotherapy CA19-9 Kinetics Correlate With Outcomes in Patients With Pancreatic Adenocarcinoma. Pancreas 2014, 43: 777-783. PMID: 24632549, DOI: 10.1097/mpa.0000000000000098.Peer-Reviewed Original ResearchConceptsPostoperative chemoradiotherapyPancreatic ductal adenocarcinomaDuctal adenocarcinomaNonmetastatic pancreatic ductal adenocarcinomaCA19-9 kineticsPretreatment CA19-9Carbohydrate antigen 19Definitive chemoradiotherapyRadiotherapy correlatesOverall survivalMultivariable analysisAntigen 19CA19-9Disease progressionPancreatic adenocarcinomaTreatment decisionsChemoradiotherapyPrognostic toolPatientsKinetics correlateAdenocarcinomaRT correlateFFPTTNProgression